Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Surgery. 2011 Feb 5;149(4):484–495. doi: 10.1016/j.surg.2010.11.014

FIG. 3.

FIG. 3

Multiple treatments with A or/and L-A-5-RIP-TK/GCV prolongs survival of PANC-1 tumor bearing mice. PANC-1 tumor mice were grouped to receive (1) 4 cycles of GCV, (2) 1 cycle of A-5-RIP-TK/GCV, (3) 1 cycle of A-5-RIP-TK/GCV+1 cycles of L-A-5-RIP-TK/GCV, (4) 1 cycle of A-5-RIP-TK/GCV+2 cycles of L-A-5-RIP-TK/GCV, (5) 1 cycle of A-5-RIP-TK/GCV+3 cycles of L-A-RIP-TK/GCV. Mice survival was estimated by using the Kaplan-Meier and log rank tests. All the treatment group had significant prolonged survival as compared to control group treated with GCV. Three cycle of A and L-A-5-RIP-TK/GCV treatment obtained longest survival among all of groups (P<0.05).